Companies: 10,795·Total market cap: $144.5T
Caris Life Sciences, Inc.

Caris Life Sciences, Inc.

CAINASDAQHealthcare● Active
$16.14
$-0.35(-2.12%)
Market Cap$4.6B
P/E Ratio—
52W High$42.5
52W Low$14.19
Free Cash FlowFinancialsRevenue

Caris Life Sciences, Inc. (CAI) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CAI · free cash flow · updated Jun 9, 2026

Core FCF metrics

Free cash flow was $66.9M for FY2025 (fiscal year ending 2025-12-31), up 126.4% year-over-year The FCF margin was 8.2%.

FY2025 Free Cash Flow$66.9M▲ +126.4% YoY
Trailing 12M (TTM)$123.5Mtrailing 4 quarters sum
FCF Margin8.2%$66.9M ÷ revenue
3-Year CAGRN/AN/A — contains negative FCF
5-Year CAGRN/AN/A — contains negative FCF
FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0
Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

Positive FCFNegative FCF
Free Cash Flow
YoY Growth %
cai free cash flow history · cai free cash flow chart · cai free cash flow growth rate · cai free cash flow last 10 years

Annual free cash flow data

Fiscal YearFree Cash FlowYoY ChangeFCF Margin
FY2025Latest$66.9M▲ +126.4%8.2%
FY2024−$253.6M▲ +15.0%-61.5%
FY2023−$298.4M▲ +9.0%-97.5%
FY2022−$328.0M▼ 669.7%-126.9%
FY2020$57.6M▲ +188.4%19.6%
FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP
cai free cash flow 2025 · cai free cash flow 2024 · cai free cash flow 2023 · cai operating cash flow

FCF valuation metrics

Caris Life Sciences, Inc. (CAI) trades at a FCF yield of 2.59% and a price-to-free-cash-flow ratio of 230.6x. FCF per share stands at $0.07, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)
2.59%
Free Cash Flow ÷ Market Cap
per FMP freeCashFlowYieldTTM definition
FCF per Share (TTM)
$0.07
TTM FCF ÷ Shares Outstanding
Price / FCF
x230.6
Share Price ÷ FCF per Share
EV / FCF (TTM)
x31.9
Enterprise Value basis
Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31
cai price to free cash flow · cai free cash flow yield · cai free cash flow per share · cai price to cash flow ratio

Cash flow statement summary

For FY2025, Caris Life Sciences, Inc. generated $83.2M in operating cash flow and spent 16M in capital expenditures, yielding $66.9M in free cash flow.

Operating Activities
+$83.2M
Cash from core business operations
2025-12-31
Investing Activities
−$16.3M
CapEx, acquisitions & investments
2025-12-31
Financing Activities
+$665.0M
Buybacks, dividends & debt
2025-12-31
FCF FormulaOperating CF ($83.2M) − |CapEx| (16M) = FCF ($66.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →
cai cash flow statement · cai cash flow statement 2025 · cai operating cash flow · cai cash flow from operations

Free cash flow vs peers (Healthcare)

#CompanyFree Cash FlowYoY
#1
Caris Life Sciences, Inc.
Caris Life Sciences, Inc.YOU
CAI
$66.9M+126.4%
#2
Johnson & Johnson
Johnson & Johnson
JNJ
$19.70B-0.7%#3
AbbVie Inc.
AbbVie Inc.
ABBV
$17.82B-0.1%#4
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$16.07B-22.4%#5
Eli Lilly and Company
Eli Lilly and Company
LLY
$8.97B+2065.6%
Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Caris Life Sciences, Inc. (CAI) reported free cash flow of $66.9M for FY2025 (fiscal year ending 2025-12-31), up 126.4% year-over-year. The FCF margin was 8.2%.

Based on available data, Caris Life Sciences, Inc. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $66.9M in FY2025.

Caris Life Sciences, Inc.'s FCF yield is 2.59% and price-to-FCF ratio is 230.6x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.
RevenueFinancial statementsNet incomeEarningsForecastPrice historyMarket capCash on handP/E ratio

Frequently asked questions

CAI free cash flow · 8 questions

Caris Life Sciences, Inc. free cash flow was $66.9M for FY2025, up 126.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $123.5M.

CAI free cash flowCAI FCFCAI FCF 2025CAI free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Caris Life Sciences, Inc. · Caris Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026